Pacira Pharmaceuticals (PCRX) PT Raised to $63 at RBC Capital
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $24.67 +3.52%
Rating Summary:
12 Buy, 15 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
12 Buy, 15 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
RBC Capital analyst Randall Stanicky raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $63.00 (from $62.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Sinclair Broadcasting (SBGI) PT Raised to $15 at JPMorgan
- Advance Auto Parts (AAP) PT Lowered to $55 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
